| Literature DB >> 35732854 |
Abstract
The classification of effects caused by mixtures of agents as synergistic, antagonistic or additive depends critically on the reference model of 'null interaction'. Two main approaches to describe co-operative effects are currently in use, the Additive Dose (ADM) or concentration addition (CA) and the Multiplicative Survival (MSM) or independent action (IA) models. Recently we proposed an approach which describes 'zero-interaction' surfaces based on the only requirement that simultaneous administration of different drugs leads to Hill-type response surfaces, which are solutions of the underlying logistic differential equations. No further assumptions, neither on mechanisms of action nor on limitations of parameter combinations are required. This defines-and limits-the application range of our approach. Resting on the same principle, we extend this ansatz in the present paper in order to describe deviations from the reference surface by generalized Hill-type functions. To this end we introduce two types of parameters, perturbations of the pure drug Hill-parameters and interaction parameters that account for n-tuple interactions between all components of a mixture. The resulting 'full-interaction' response surface is a valid solution of the basic partial differential equation (PDE), satisfying appropriate boundary conditions. This is true irrespective of its actual functional form, as within our framework the number of parameters is not fixed. We start by fitting the experimental data to the 'full-interaction' model with the maximum possible number of parameters. Guided by the fit-statistics, we then gradually remove insignificant parameters until the optimum response surface model is obtained. The 'full-interaction' Hill response surface ansatz can be applied to mixtures of n compounds with arbitrary Hill parameters including those describing baseline effects. Synergy surfaces, i.e., differences between full- and null-interaction models, are used to identify dose-combinations showing peak synergies. We apply our approach to binary and ternary examples from the literature, which range from mixtures behaving according to the null-interaction model to those showing strong synergistic or antagonistic effects. By comparing 'null-' and 'full-response' surfaces we identify those dose-combinations that lead to maximum synergistic or antagonistic effects. In one example we identify both synergistic and antagonistic effects simlutaneously, depending on the dose-ratio of the components. In addition we show that often the number of parameters necessary to describe the response can be reduced without significantly affecting the accuracy. This facilitates an analysis of the synergistic effects by focussing on the main factors causing the deviations from 'null-interaction'.Entities:
Mesh:
Year: 2022 PMID: 35732854 PMCID: PMC9217971 DOI: 10.1038/s41598-022-13469-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Anesthetic mixtures: Exptl. data vs. ’full’- and ’null’-interaction models.
| Midazolam | Propofol | Alfentanil | exptl. | Fit results, based on parameters from: | ||
|---|---|---|---|---|---|---|
| Riccati | Riccati | Hill | ||||
| 0.1 | 0 | 0 | 0.2 | 0.1 | 0.1 | |
| 0.125 | 0 | 0 | 0.3 | 0.3 | 0.3 | |
| 0.15 | 0 | 0 | 0.5 | 0.5 | 0.5 | |
| 0.175 | 0 | 0 | 0.8 | 0.7 | 0.7 | |
| 0.2 | 0 | 0 | 0.8 | 0.8 | 0.8 | |
| 0 | 0.7 | 0 | 0.1 | 0 | 0. | |
| 0 | 1 | 0 | 0.3 | 0.3 | 0.3 | |
| 0 | 1.3 | 0 | 0.9 | 0.9 | 0.9 | |
| 0 | 1.6 | 0 | 1 | 1 | 1 | |
| 0 | 1.9 | 0 | 1 | 1 | 1 | |
| 0 | 2.2 | 0 | 1 | 1 | 1 | |
| 0 | 2.5 | 0 | 1 | 1 | 1 | |
| 0 | 0 | 0.05 | 0 | 0.1 | 0 | |
| 0 | 0 | 0.075 | 0.3 | 0.2 | 0.2 | |
| 0 | 0 | 0.1 | 0.5 | 0.6 | 0.6 | |
| 0 | 0 | 0.125 | 0.9 | 0.8 | 0.8 | |
| 0 | 0 | 0.15 | 1 | 1 | 0.9 | |
| 0.03 | 0.21 | 0 | 0.2 | 0.2 | 0.2 | 0.0 |
| 0.04 | 0.29 | 0 | 0.4 | 0.4 | 0.4 | 0.0 |
| 0.05 | 0.36 | 0 | 0.5 | 0.6 | 0.6 | 0.0 |
| 0.065 | 0.46 | 0 | 0.8 | 0.8 | 0.3 | 0.3 |
| 0.085 | 0.6 | 0 | 1 | 0.9 | 0.8 | 0.7 |
| 0.1 | 0.71 | 0 | 1 | 1 | 0.9 | 0.9 |
| 0.13 | 0.92 | 0 | 1 | 1 | 1 | 1.0 |
| 0.17 | 1.2 | 0 | 1 | 1 | 1 | 1.0 |
| 0 | 0.25 | 0.025 | 0.1 | 0.1 | 0.0 | 0.0 |
| 0 | 0.31 | 0.031 | 0.3 | 0.2 | 0.2 | 0.0 |
| 0 | 0.4 | 0.04 | 0.4 | 0.5 | 0.6 | 0.1 |
| 0 | 0.5 | 0.049 | 0.8 | 0.7 | 0.8 | 0.5 |
| 0 | 0.63 | 0.061 | 0.9 | 0.9 | 0.9 | 0.9 |
| 0.035 | 0 | 0.025 | 0.4 | 0.4 | 0.0 | 0.0 |
| 0.044 | 0 | 0.031 | 0.7 | 0.7 | 0.2 | 0.1 |
| 0.056 | 0 | 0.04 | 0.9 | 0.9 | 0.6 | 0.3 |
| 0.07 | 0 | 0.049 | 0.9 | 0.9 | 0.8 | 0.5 |
| 0.085 | 0 | 0.061 | 1 | 1 | 0.9 | 0.8 |
| 0.023 | 0.17 | 0.016 | 0.3 | 0.3 | 0. | |
| 0.03 | 0.21 | 0.021 | 0.6 | 0.6 | 0. | |
| 0.037 | 0.26 | 0.026 | 0.8 | 0.8 | 0.1 | |
| 0.047 | 0.33 | 0.032 | 0.9 | 0.9 | 0.5 | |
| 0.059 | 0.42 | 0.041 | 1 | 1 | 0.8 | |
Data from[41], 0 = no hypnosis, 1 = full hypnosis.
Full-interaction model , Eqs. (8) and (23), interaction parameters from Table 1.
Hill’s equation for pure compounds, null-interaction model , Eq. (4), else.
Figure 1Contour plots of ADH inhibitor synergy surfaces (in %) using different parameter sets for . The surfaces contain (a) -only, (b) all interaction parameters , and , and (c) the full-parameter set.
Fit characteristics and parameters of anesthetics and their mixtures.
| Drug | Minto[ | Hill | Riccati | Interaction terms | peak | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIC | RMSE | MW | RMSE | AIC | MW | |||||||
| Midazolam | 0.144 | 4.8 | 0.054 | 0.053 | ||||||||
| Propofol | 1.078 | 11.1 | 0.035 | 0.035 | ||||||||
| Alfentanil | 0.093 | 5.7 | 0.069 | 0.069 | ||||||||
| Midazolam + Propofol | − 58.97 | 0.387 | 0.13 | 0.043 | − 60.54 | 0.65 | 0.14 | − 12.89 | 1.11 | 65 | ||
| Midazolam + Alfentanil | − 36.33 | 0.477 | 0.21 | 0.051 | − 37.64 | 0.97 | − 0.08 | 1.28 | 1.68 | 66 | ||
| Propofol + Alfentanil | − 35.09 | 0.228 | 0.37 | 0.053 | − 42.68 | 0.63 | 0.35 | − 12.34 | 0.38 | 37 | ||
| Ternary mixture | − 106.75 | 0.461 | 0.09 | 0.046 | − 121.06 | 0.79 | 0.00 | 2.46 | − 1.16 | 68 | ||
| | 0.13 | − 12.84 | 1.11 | |||||||||
| | − 0.09 | 1.56 | 1.69 | |||||||||
| | 0.23 | − 11.78 | 0.40 | |||||||||
, fraction of dose causing hypnosis in 50% of the population.
Slope of the dose-response curve.
Null-interaction model, Eq. (4).
Full interaction model, Eq. (35).
Between maximum effects , slopes and inflection points (, , for ternary mixture)
Calculated effect-difference between full- and null-interaction models, [%].
Goodness of fit according to the Akaike Information Criterion.
RMSE = root-mean-square error with respect to exptl. data.
p-values from the Wilcoxon-Mann-Whitney test.
Propofol, Midazolam, Alfentanil.
Figure 2Synergy surfaces for binary mixtures of anesthetics, based on of Eq. (35), with parameters , and from Table 1. Doses in [mg/kg]. Green dots denote dose combinations leading to peak synergistic effects.
AhR agonist parameters from GCA- and Hill-models.
| Ligand | GCA, | Hill, | |||
|---|---|---|---|---|---|
| TCDF | 100 | 100 | 0.88 | ||
| PCB126 | 99 | 100 | 0.82 | ||
| TCDD | 100 | 100 | 1.29 | ||
| PCB105 | 61 | 56 | 1.45 | ||
| TCDD | 100 | 100 | 1.09 | ||
| Galangin | 30 | 35 | 0.79 | ||
| TCDD | 100 | 100 | 1.22 | ||
| DIM | 8 | 10 | 1.62 | ||
Parameters are slopes , maximum effects and values of the agents.
2,3,7,8-tetrachlorodibenzofuran;
2,3,3’,4,4’-petachlorobiphenyl;
2,3,7,8-tetrachlorodibenz-p-dioxin;
3,3’-diindolylmethane.
Figure 3Iso-response surfaces for the ternary anesthetic mixture of propofol, midazolam and alfentanil at 25%, 50%, and 75% effect levels. Doses in [mg/kg]. Shown for the null-interaction (a) and the ’full-interaction’ (b) models. Their difference (c) shows iso-synergy surfaces at 10%, 30% and 50% levels.
AhR agonist parameters for ’null’- and ’full’-interaction surfaces.
| Mixture | Set | Perturbation terms | Interaction terms | RMSE | AIC | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCDF | 0 | – | – | – | – | – | – | – | – | – | 4.5 | |
| 1” | – | – | – | – | − 0.15 | 0.02 | – | – | – | 3.6 | − 157.5 | |
| 1’ | – | – | 1.05 | 0.91 | − 0.13 | − 0.01 | – | – | – | 3.5 | − 155.8 | |
| 1 | − 0.05 | 0.00 | 0.92 | 0.91 | − 0.04 | − 0.01 | – | – | – | 3.4 | − 153.2 | |
| 2 | – | – | – | – | – | – | 0.01 | − 0.37 | 0.18 | 3.8 | − 151.1 | |
| 3 | – | – | – | – | –0.13 | 0.05 | 0.04 | − 0.40 | 0.17 | 3.6 | − 152.8 | |
| 4 | – | – | 1.08 | 0.94 | − 0.11 | 0.03 | 0.02 | − 0.32 | 0.157 | 3.5 | − 149.9 | |
| 5 | − 0.05 | 0.00 | 0.93 | 0.93 | − 0.01 | 0.02 | 0.06 | − 0.36 | − 0.01 | 3.4 | − 146.8 | |
| TCDD | 0 | – | – | – | – | – | – | – | – | – | 8.0 | |
| 1” | – | – | – | – | − 0.28 | − 0.66 | – | – | – | 6.6 | − 112.3 | |
| 1’ | – | – | 1.29 | 0.91 | − 0.13 | − 0.62 | – | – | – | 6.1 | − 112.8 | |
| 1 | 0.0 | − 0.10 | 1.22 | 0.61 | − 0.10 | 0.09 | – | – | – | 5.0 | − 126.6 | |
| 2 | – | – | – | – | – | – | − 0.41 | − 0.53 | 0.40 | 5.6 | − 124.4 | |
| 3 | – | – | – | – | 0.01 | − 0.33 | − 0.38 | − 0.26 | 0.25 | 5.5 | − 121.2 | |
| 4 | – | – | 1.07 | 0.85 | 0.07 | − 0.40 | − 0.35 | 0.00 | 0.16 | 5.4 | − 118.0 | |
| 5 | − 0.05 | 0.00 | 0.93 | 0.93 | − 0.01 | 0.02 | 0.06 | − 0.36 | − 0.01 | 4.5 | − 130.8 | |
| TCDD + Galangin | 0 | – | – | – | – | – | – | – | – | – | 7.1 | |
| 1” | – | – | – | – | − 0.08 | − 0.19 | – | – | – | 7.0 | − 108.0 | |
| 1’ | – | – | 0.91 | 0.46 | 0.13 | − 0.14 | – | – | – | 5.9 | − 119.8 | |
| 1 | 0.0 | − 0.06 | 1.13 | 0.57 | 0.03 | 2.52 | – | – | – | 5.5 | − 121.9 | |
| 2 | – | – | – | – | – | – | − 0.45 | 7.3 | 2.30 | 5.5 | − 128.8 | |
| 3 | – | – | – | – | 0.15 | − 0.34 | 0.62 | − 2.85 | 4.85 | 5.1 | − 130.3 | |
| 4 | – | – | 0.92 | 0.11 | − 0.04 | − 0.46 | − 0.18 | 8.12 | − 0.18 | 4.9 | − 129.7 | |
| 5 | 0.0 | − 0.02 | 0.50 | − 0.43 | − 0.04 | − 0.35 | − 0.10 | 8.73 | − 0.41 | 4.9 | − 125.7 | |
| TCDD + DIMi | 0 | – | – | – | – | – | – | – | – | – | 14.2 | |
| 1” | – | – | – | – | − 0.50 | − 1.32 | – | – | – | 9.9 | − 83.8 | |
| 1’ | – | – | 1.10 | 0.17 | 0.28 | − 0.19 | – | – | – | 4.0 | − 181.4 | |
| 1 | 0.0 | − 0.01 | 1.08 | 0.17 | 0.24 | 0.01 | – | – | – | 4.0 | − 177.3 | |
| 2 | – | – | – | – | – | – | 0.02 | − 2.47 | − 1.83 | 5.5 | − 129.4 | |
| 3 | – | – | – | – | 0.20 | − 0.21 | − 0.05 | − 2.74 | − 1.88 | 5.3 | − 146.2 | |
| 4 | – | – | 0.92 | 0.11 | − 0.09 | − 0.94 | 0.16 | 1.54 | − 0.66 | 3.8 | − 181.8 | |
| 5 | 0.0 | − 0.05 | 1.00 | 0.10 | 0.28 | 0.78 | 0.31 | − 0.85 | − 0.58 | 3.7 | − 178.5 | |
Perturbation of maximum effects ,, inflection points , and slopes ,, in Eq. (19) corresponds to , the same holds true for .
Interaction between maximum effects , slopes and inflection points .
See legends of Table 1.
See legends of Table 3.
Figure 4Synergy surfaces of binary AhR ligand mixtures (in %) , obtained as using the respective optimum parameter set from Table 4, according to the AIC criterion. Dashed lines denote maximum doses used in the experiments. The observed responses range from null-interaction within exptl. error (a) TCDF+PCB126 (parameter set 1”) and (b) TCDD+PCB105 (parameter set 5) to simultaneous presence of synergism and antagonism (c) TCDD+Galangin (parameter set 3) and clear antagonism (d) TCDD+DIM (parameter set 4). Green an red dots refer to minima and maxima of the synergy surfaces.
Minima and maxima of synergy surfaces: peak synergism/antagonism for AhR agonists.
| Mixture | Peak dose combination | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dose a | Dose b | ||||||||
| TCDF | 66 | 68 | 2 | 2 | 7 | 2 | 5 | ||
| 95 | 90 | − 5 | − 4 | − 4 | − 4 | − 3 | |||
| TCDD | 28 | 34 | 5 | 5 | 3 | 1 | 3 | ||
| 79 | 65 | − 15 | − 14 | − 14 | − 13 | − 13 | |||
| TCDD + Galangin | 71 | 85 | 14 | 13 | 40 | 7 | 22 | ||
| 33 | 7 | − 27 | − 24 | − 13 | − 13 | − 12 | |||
| TCDD + DIMe | 3 | 13 | 10 | 11 | 11 | 7 | 11 | ||
| 73 | 38 | − 35 | − 35 | − 36 | − 35 | − 30 | |||
Peak-difference between calculated full-() and null-interaction () responses at the respective dose-combinations of (corresponding dose combinations not shown for the to surfaces). Subscripts denote the parameter sets from Table 4.
See legends of Table 3.
Values of are assumed to be within the exptl. errors.